Related Experiment Video

Updated: Aug 7, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Mutagenicity studies on fenticonazole, a new antifungal imidazole derivative

M Veronese, D Barzaghi, A Bertoncini

    Arzneimittel-Forschung
    |January 1, 1981
    PubMed

    Insights

    Fenticonazole, an antifungal drug, was tested for mutagenicity using yeast assays. Results indicate that fenticonazole does not exhibit mutagenic activity in these tests.

    Area of Science:

    • Microbiology
    • Genetics
    • Toxicology

    Background:

    • Antifungal agents are crucial in treating infections.
    • Assessing the mutagenic potential of drugs is vital for safety.
    • Fenticonazole is a broad-spectrum antifungal agent.

    Purpose of the Study:

    • To evaluate the mutagenic potential of fenticonazole.
    • To determine if fenticonazole poses a risk of genetic mutations.

    Main Methods:

    • Utilized the forward mutational assay in Schizosaccharomyces pombe.
    • Employed the mitotic gene conversion assay in Saccharomyces cerevisiae.
    • Compared fenticonazole's activity against known mutagenic standards.

    Main Results:

    • Fenticonazole showed no mutagenic activity in the Schizosaccharomyces pombe assay.
    • Fenticonazole demonstrated no mutagenic activity in the Saccharomyces cerevisiae assay.
    • No significant difference in mutagenicity was observed compared to standards.

    Conclusions:

    • Fenticonazole does not appear to possess mutagenic activity.
    • The tested yeast assays suggest fenticonazole is safe regarding mutagenicity.
    • Further safety assessments may be warranted based on these findings.

    More Related Videos

    Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

    Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

    Published on: February 14, 2018

    Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells09:27

    Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

    Published on: April 2, 2021

    Related Concept Videos

    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    Antifungal Agents01:15

    Antifungal Agents

    Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...